1887

Abstract

Purpose. The occurrence of carbapenem- and colistin-resistance among Gram-negative bacteria is increasing worldwide. The aim of this study was to understand the distribution of carbapenem- and colistin-resistance in two areas in Tamil Nadu, India.

Methodology. The clinical isolates (n=89) used in this study were collected from two diagnostic centres in Tamil Nadu, India. The bacterial isolates were screened for meropenem- and colistin-resistance. Further, resistance genes bla NDM-1, bla OXA-48-like, bla IMP, bla VIM, bla KPC, mcr-1 and mcr-2 and integrons were studied. The synergistic effect of meropenem in combination with colistin was assessed.

Results. A total of 89 bacterial isolates were studied which included Escherichia coli (n=43), Klebsiella pneumoniae (n=18), Pseudomonas aeruginosa (n=10), Enterobacter cloacae (n=6), Acinetobacter baumannii (n=5), Klebsiella oxytoca (n=4), Proteus mirabilis (n=2) and Salmonella paratyphi (n=1). MIC testing showed that 58/89 (65 %) and 29/89 (32 %) isolates were resistant to meropenem and colistin, respectively, whereas 27/89 (30 %) isolates were resistant to both antibiotics. Escherichia coli, K. pneumoniae, K. oxytoca, Pseudomonas aeruginosa, and Enterobacter cloacae isolates were bla NDM-1-positive (n=20). Some strains of Escherichia coli, K. pneumoniae and K. oxytoca were bla OXA-181-positive (n=4). Class 1, 2 and 3 integrons were found in 24, 20 and 3 isolates, respectively. Nine NDM-1-positive Escherichia coli strains could transfer carbapenem resistance via plasmids to susceptible Escherichia coli AB1157. Meropenem and colistin showed synergy in 10/20 (50 %) isolates by 24 h time-kill studies.

Conclusion. Our results highlight the distribution of carbapenem- and colistin-resistance in Gram-negative bacteria isolated from the Tamil Nadu region in South India.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000508
2017-07-03
2019-09-18
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/7/874.html?itemId=/content/journal/jmm/10.1099/jmm.0.000508&mimeType=html&fmt=ahah

References

  1. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003;36:1433–1437 [CrossRef][PubMed]
    [Google Scholar]
  2. Xu Y, Gu B, Huang M, Liu H, Xu T et al. Epidemiology of carbapenem resistant Enterobacteriaceae (CRE) during 2000-2012 in Asia. J Thorac Dis 2015;7:376–385 [CrossRef][PubMed]
    [Google Scholar]
  3. Perez F, Van Duin D. Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients. Cleve Clin J Med 2013;80:225–233 [CrossRef][PubMed]
    [Google Scholar]
  4. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E et al. Comparative review of the carbapenems. Drugs 2007;67:1027–1052 [CrossRef][PubMed]
    [Google Scholar]
  5. Falagas ME, Kasiakou SK, Saravolatz LD. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005;40:1333–1341 [CrossRef][PubMed]
    [Google Scholar]
  6. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF et al. Antibiotic resistance: the need for global solutions. Lancet Infect Dis 2013;13:1057–1098 [CrossRef][PubMed]
    [Google Scholar]
  7. Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012;18:413–431 [CrossRef][PubMed]
    [Google Scholar]
  8. Livermore DM. Has the era of untreatable infections arrived?. J Antimicrob Chemoth 2009;64:i29–i36 [CrossRef][PubMed]
    [Google Scholar]
  9. Capone A, Giannella M, Fortini D, Giordano A, Meledandri M et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013;19:E23E30 [CrossRef][PubMed]
    [Google Scholar]
  10. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012;18:18–29 [CrossRef][PubMed]
    [Google Scholar]
  11. Nation RL, Li J. Colistin in the 21st century. Curr Opin Infect Dis 2009;22:535–543 [CrossRef][PubMed]
    [Google Scholar]
  12. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009;9:228–236 [CrossRef][PubMed]
    [Google Scholar]
  13. Li J, Rayner CR, Nation RL, Owen RJ, Spelman D et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006;50:2946–2950 [CrossRef][PubMed]
    [Google Scholar]
  14. Vila-Farres X, Garcia de La Maria C, López-Rojas R, Pachón J, Giralt E et al. In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin Microbiol Infect 2012;18:383–387 [CrossRef][PubMed]
    [Google Scholar]
  15. Ramesh N, Prasanth M, Ramkumar S, Suresh M, Tamhankar AJ et al. Colistin susceptibility of Gram-negative clinical isolates from Tamil Nadu, India. Asian Biomed 2016;10:35–39
    [Google Scholar]
  16. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis 2016;16:161–168 [CrossRef][PubMed]
    [Google Scholar]
  17. Du H, Chen L, Tang YW, Kreiswirth BN. Emergence of the mcr-1 colistin resistance gene in carbapenem-resistant Enterobacteriaceae. Lancet Infect Dis 2016;16:287–288 [CrossRef][PubMed]
    [Google Scholar]
  18. Xavier BB, Lammens C, Ruhal R, Kumar-Singh S, Butaye P et al. Identification of a novel plasmid-mediated colistin-resistance gene, mcr-2, in Escherichia coli, Belgium, June 2016. Eurosurveillance 2016;21:pii=30280 [CrossRef]
    [Google Scholar]
  19. Vila J, Martí S, Sánchez-Céspedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J Antimicrob Chemother 2007;59:1210–1215 [CrossRef][PubMed]
    [Google Scholar]
  20. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011;37:415–419 [CrossRef][PubMed]
    [Google Scholar]
  21. Krauland MG, Marsh JW, Paterson DL, Harrison LH. Integron-mediated multidrug resistance in a global collection of nontyphoidal Salmonella enterica isolates. Emerg Infect Dis 2009;15:388–396 [CrossRef]
    [Google Scholar]
  22. Tajbakhsh E, Khamesipour F, Ranjbar R, Ugwu IC. Prevalence of class 1 and 2 integrons in multi-drug resistant Escherichia coli isolated from aquaculture water in Chaharmahal Va Bakhtiari province, Iran. Ann Clin Microbiol Antimicrob 2015;14:37 [CrossRef][PubMed]
    [Google Scholar]
  23. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791–1798 [CrossRef]
    [Google Scholar]
  24. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement, Approved standard M100-S25. Wayne, PA: CLSI; 2015
    [Google Scholar]
  25. Nagdeo NV, Kaore NM, Thombare VR. Phenotypic methods for detection of various β-lactamases in Gram-negative clinical isolates: need of the hour. Chron Young Sci 2012;3:292[CrossRef]
    [Google Scholar]
  26. Pankuch GA, Lin G, Seifert H, Appelbaum PC. Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrob Agents Chemother 2008;52:333–336 [CrossRef][PubMed]
    [Google Scholar]
  27. Doyle D, Peirano G, Lascols C, Lloyd T, Church DL et al. Laboratory detection of Enterobacteriaceae that produce carbapenemases. J Clin Microbiol 2012;50:3877–3880 [CrossRef][PubMed]
    [Google Scholar]
  28. Kargar M, Mohammadalipour Z, Doosti A, Lorzadeh S, Japoni-Nejad A. High prevalence of class 1 to 3 integrons among multidrug-resistant diarrheagenic Escherichia coli in southwest of Iran. Osong Public Health Res Perspect 2014;5:193–198 [CrossRef][PubMed]
    [Google Scholar]
  29. Versalovic J, Schneider M, de Bruijn FJ, Lupski JR. Genomic fingerprinting of bacteria using repetitive sequence-based polymerase chain reaction. Methods Mol Cell Biol 1994;5:25–40
    [Google Scholar]
  30. Vaidya VK. Horizontal transfer of antimicrobial resistance by extended-spectrum β lactamase-producing Enterobacteriaceae. J Lab Physicians 2011;3:37 [CrossRef][PubMed]
    [Google Scholar]
  31. Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN et al. Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007. Antimicrob Agents Chemother 2011;55:1274–1278 [CrossRef][PubMed]
    [Google Scholar]
  32. Lascols C, Hackel M, Marshall SH, Hujer AM, Bouchillon S et al. Increasing prevalence and dissemination of NDM-1 metallo-β-lactamase in India: data from the SMART study (2009). J Antimicrob Chemother 2011;66:1992–1997 [CrossRef][PubMed]
    [Google Scholar]
  33. Srinivasan R, Ellappan K, Narasimha HB. Prevalence and characterization of NDM-1 and OXA-48 carbapenemase gene harboring Enterobacteriaceae in a tertiary care hospital, South India. African J Bacteriol Res 2015;7:60–63
    [Google Scholar]
  34. Nachimuthu R, Subramani R, Maray S, Gothandam KM, Sivamangala K et al. Characterization of carbapenem-resistant Gram-negative bacteria from Tamil Nadu. J Chemother 2016;28:371–374 [CrossRef][PubMed]
    [Google Scholar]
  35. Poirel L, Kieffer N, Liassine N, Thanh D, Nordmann P. Plasmid-mediated carbapenem and colistin resistance in a clinical isolate of Escherichia coli. Lancet Infect Dis 2016;16:281 [CrossRef][PubMed]
    [Google Scholar]
  36. Nordmann P, Lienhard R, Kieffer N, Clerc O, Poirel L. Plasmid-mediated colistin-resistant Escherichia coli in bacteremia in Switzerland. Clin Infect Dis 2016;62:1322–1323 [CrossRef][PubMed]
    [Google Scholar]
  37. Norgan AP, Freese JM, Tuin PM, Cunningham SA, Jeraldo PR et al. Carbapenem- and colistin-resistant Enterobacter cloacae from Delta, Colorado, in 2015. Antimicrob Agents Chemother 2016;60:3141–3144 [CrossRef][PubMed]
    [Google Scholar]
  38. Pragasam AK, Shankar C, Veeraraghavan B, Biswas I, Nabarro LE et al. Molecular mechanisms of colistin resistance in Klebsiella pneumoniae causing bacteremia from India: a first report. Front Microbiol 2016;7:2135 [CrossRef][PubMed]
    [Google Scholar]
  39. Mohsin M, Raza S, Roschanski N, Guenther S, Ali A et al. Description of the first Escherichia coli clinical isolate harboring the colistin resistance gene mcr-1 from the Indian subcontinent. Antimicrob Agents Chemother 2016;61:e01945-16 [CrossRef][PubMed]
    [Google Scholar]
  40. Du H, Chen L, Tang YW, Kreiswirth BN. Emergence of the mcr-1 colistin resistance gene in carbapenem-resistant Enterobacteriaceae. Lancet Infect Dis 2016;16:287–288 [CrossRef][PubMed]
    [Google Scholar]
  41. Yao X, Doi Y, Zeng L, Lv L, Liu JH. Carbapenem-resistant and colistin-resistant Escherichia coli co-producing NDM-9 and MCR-1. Lancet Infect Dis 2016;16:288–289 [CrossRef][PubMed]
    [Google Scholar]
  42. Rojo-Bezares B, Cavalié L, Dubois D, Oswald E, Torres C et al. Characterization of carbapenem resistance mechanisms and integrons in Pseudomonas aeruginosa strains from blood samples in a French hospital. J Med Microbiol 2016;65:311–319 [CrossRef][PubMed]
    [Google Scholar]
  43. Morrill HJ, Pogue JM, Kaye KS, Laplante KL. Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis 2015;5:ofv050
    [Google Scholar]
  44. Betts JW, Phee LM, Woodford N, Wareham DW. Activity of colistin in combination with tigecycline or rifampicin against multidrug-resistant Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis 2014;33:1565–1572 [CrossRef][PubMed]
    [Google Scholar]
  45. Parchem NL, Bauer KA, Cook CH, Mangino JE, Jones CD et al. Colistin combination therapy improves microbiologic cure in critically ill patients with multi-drug resistant Gram-negative pneumonia. Eur J Clin Microbiol Infect Dis 2016;35:1433–1439 [CrossRef][PubMed]
    [Google Scholar]
  46. Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014;dku168
    [Google Scholar]
  47. Cheng A, Chuang YC, Sun HY, Sheng WH, Yang CJ et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med 2015;43:1194–1204 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000508
Loading
/content/journal/jmm/10.1099/jmm.0.000508
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error